According to TechCrunch, how do you find a way to treat amyotrophic lateral sclerosis (ALS)? This is the problem that BenevenentBio CEO Jackie Hunter is facing. It is a biomedical subsidiary of the artificial intelligence company BenevolentAI. The company applies machine learning to vast amounts of data in medical research to quickly scan and organize data. However, changing scientific methods does not mean that new discoveries can be made, but the latest research on life sciences is updated every 30 seconds, and many valuable studies are often missed.
Hunter said that Benevolent Bio's artificial intelligence (AI) has been successful in scanning studies that may contain secrets to treat ALS disease. Hunter explained: "Our focus is on testing five complexes from cloned cells of ALS patients' own cells. One of the complexes has no therapeutic effect, two of which meet the gold standard for ALS treatment, and another 2 The treatment is better. Four of the five compounds are things that researchers have never considered."
Since BenevolentBio tests all the drugs that have already been developed, it may be applied more quickly to the clinical treatment of patients than the newly discovered drugs. Hunter said: "I am from the pharmaceutical industry. The development process in this field has not changed in the past few decades. Developing a drug may require $2 billion." By using AI, drug developers can discover drugs. For other uses, there is no need to invest heavily in new drugs. In addition, AI can help scientists make more promising discoveries faster.
Puyang Linshi Medical Supplies Co., Ltd. , https://www.linshihealths.com